Elicio is a biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology.
Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer.
Elicio Therapeutics was founded in 2011 by Darrell Irvine and Satish Jindal. The company is headquartered in Cambridge, Massachusetts.
Elicio Therapeutics is advancing the Amphiphile technology across immunotherapy platforms to defeat cancers and infectious diseases.
Elicio is engineering potent Amphiphile immunotherapies that precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated.
Elicio’s AMP platform technology has created a robust set of valuable assets. The platform technology has been used to improve the activity of immunostimulatory agents, antigens, adjuvants, and cell-therapies that generate little to no response when used in the conventional forms.
ELicio has collaborations with top institutions such as MIT, National Cancer Institute, Moffitt Cancer Center, Boston Children’s Hospital, and QIMR Berghofer Medical Research Institute, advancing the AMP platform, AMP cell therapies, therapeutic vaccines etc.
Elicio is backed by Access BridgeGap Ventures, Clal Biotechnology Industries, Livzon Pharmaceutical Group, EFung Capital and others. The company closed its Series B round totaling $73M on Feb 17, 2021. This brings Elicio's total funding to $148.5M to date.